Cosentyx 150 Mg Injection, Composition : Secukinumab

Cosentyx 150 mg (Secukinumab) injection is a prescription biologic used to treat moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. It is a human monoclonal antibody that targets interleukin-17A (IL-17A), a key cytokine in inflammatory processes. Administered subcutaneously, typically once a week for initial doses and then monthly, it helps reduce inflammation, pain, and skin symptoms. Common side effects include upper respiratory infections, diarrhea, and injection site reactions. Use under medical supervision.

 The impact of psoriasis on children is much deeper than skin and can potentially lead to life course impairment,” said Todd Fox, Global Head of Medical Affairs Immunology, Hepatology and Dermatology at Novartis. “This is the second European approval this year for Cosentyx, which also has approvals across four adult indications, reinforcing our commitment to reimagine medicine for both pediatric and adult patients.”

Children with psoriasis have a poorer quality of life than their peers due to symptoms such as itching and fatigue, in addition to feelings of stigmatization. These in turn may affect their emotional wellbeing and performance at school8.

“Children with psoriasis are susceptible to bullying, name-calling and shaming at school, leading to higher rates of depression and anxiety than their peers,” said Jan Koren, President of the European patient group EUROPSO. “We welcome this approval, as there is a need for additional treatment options that can help give children the freedom to enjoy full and active lives by improving psoriasis symptoms and thus overall quality of life.”